Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

Shoulder Innovations (NYSE: SI) and ALM Ortho partnered to develop personalized shoulder implants for complex cases. SI gains exclusive U.S. rights for upper extremity applications. The deal aims to address unmet needs and drive growth, though financial terms are confidential.

Original reporting
Published Sep 9, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures — source image
Decision brief

The 30-second read

$SIBullishLow
01

Why it matters

The exclusive U.S. rights for ALM Ortho's bespoke implants could differentiate SI's offering and attract surgeons handling complex cases.

02

Market read

A new partnership adds strategic depth to SI but lacks immediate financial impact.

03

What to watch

Potential regulatory approvals and reimbursement pathways could delay revenue realization.

Relevance 5/10Novelty 5/10Timing: Sept 9 2026 (today)

Background

Shoulder Innovations (NYSE:SI) is a commercial-stage medical technology company focused on shoulder surgery solutions.

Company-level read

Ticker impact

$SIBullishMedium confidence
Context

Shoulder Innovations announced an exclusive partnership with ALM Ortho to offer bespoke shoulder implants in the U.S.

Expected impact

modest upside potential as market digests the partnership

Evidence & confidence

New exclusive deal adds strategic capability but no financial terms disclosed, limiting immediate price impact.

Market effects

May boost the orthopedic device sector by highlighting additive manufacturing collaborations.

U.S. market focus, limited broader regional effect.

Limited to niche medical technology space.

Counterpoint

Without disclosed financial terms, the partnership may not materially affect SI's valuation.

Key entities

  • Shoulder Innovations

    Medical technology firm developing shoulder surgical solutions.

  • ALM Ortho

    Additive manufacturing specialist for orthopedic implants.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.